Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with ¹⁸F-FDOPA and ¹⁸F-FDG PET.

ABSTRACT: Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necessitating the stratification of responding patients to minimize toxicities and improve quality of life. Here, we evaluated the use of 3,4-dihydroxy-6-¹⁸F-fluoro-l-phenylalanine (¹⁸F-FDOPA), a clinically available PET radiotracer with specificity to the L-type amino acid transporter 1 (LAT1), which also mediates melphalan uptake, for imaging melphalan therapy response in a preclinical immunocompetent model of MM. Methods: C57BL/KaLwRij mice were implanted subcutaneously

SUBMITTER: Hathi DK 

PROVIDER: S-EPMC6167538 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature